Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity

NCT03523273 · Completed

Last updated 2026-05-28

This clinical trial tests whether the medication liraglutide at a 3.0 mg dose helps with weight loss and affects how quickly the stomach empties food in adults with obesity.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 136 people

Who can join Ages 18–65 · all sexes Healthy volunteers accepted.

Timeline Started 2017-11 · est. completion 2021-08

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT03523273 ↗

Description as written by the study sponsor.

This study is being done to assess the stomach emptying effect of a maximum dose of 3 mg Liraglutide compared to placebo in subjects who are overweight or obese. Liraglutide is a medication approved by the Food and Drug Administration (FDA) for routine clinical use.

Treatments tested

Liraglutide also known as Saxenda, Victoza Drug

Initiate at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6mg/day in weekly intervals to a dose of 3.0 mg/day is achieved (\~4 weeks). Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
Placebo Drug

Placebo administration will match the study drug.

Main thing measured	Gastric Emptying of Solids (T1/2)
Sponsor	Michael Camilleri, MD
Conditions studied	Obesity
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03523273 ↗